Spero Therapeutics Consensus Price Target Raised 25% to $5.10
The average one-year price target for Spero Therapeutics (NASDAQGS:SPRO) (DB:2HA) has been revised to $5.10 / share. This is an increase of 25.00% from the prior estimate of $4.08 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a recommendation orinvestment adviceby Fintel.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $4.04 to a high of $6.30 / share. The average price target represents an increase of 308.00% from the latest reported closing price of $1.25 / share as of October 1, 2026. The current target range width of $2.26 represents a widening from the prior target range width of $0.16, which is a target range width change percent of +1,312.50%. The current mean-median gap is $0.00, with both the current mean and current median standing at $5.10 as of September 29, 2026. This median represents an increase of $1.02 from the prior median of $4.08.
Looking at the target history, the mean target was $5.10 on October 2, 2026, which is also the observed twelve-month high mean date among the supplied observations. Prior to this, the mean target was $4.08 on September 16, 2026, August 28, 2026, and August 4, 2026. The observed twelve-month low mean of $4.08 was recorded on September 16, 2026. This represents a target change since the 90-day baseline of +25.00% from the baseline date of June 30, 2026. In terms of price performance, Spero Therapeutics recorded a 0.00% price change over one week from a baseline close of $1.25 on September 24, 2026. Over a one-month period, the stock experienced a price change of +4.17% from a baseline close of $1.20 on September 1, 2026.
Spero Therapeutics, Inc., based in the United States, operates within the biopharmaceutical sector, focusing primarily on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections. A key flagship project of Spero Therapeutics is its innovative product, Tebipenem HBr, which is an orally administered carbapenem antibiotic currently in advanced clinical trials aimed at treating complicated urinary tract infections (cUTI) caused by certain antibiotic-resistant pathogens. In its latest earnings report on August 12, 2026, the company reported an actual EPS of -0.16, compared to the estimated EPS of -0.1734. The actual revenue reported was $0.00.
In recent analyst actions, HC Wainwright & Co. maintained a Buy rating on Spero Therapeutics on September 14, 2026. The recommendation trend shows that for the period of September 1, 2026, there were 3 hold recommendations, 1 sell recommendation, and 2 strong sell recommendations, representing 0.0% positive, 50.0% hold, and 50.0% negative recommendations out of 6 total recommendations. This recommendation profile remained unchanged from the prior period of August 1, 2026. Within the broader Biotechnology sub-industry, which covers 24 companies, 3 companies experienced raised targets, 6 experienced lowered targets, and 15 remained unchanged. The sub-industry median revision percent was 0.00%, with a median implied change percent of +83.51%.
To provide broader industry context, several peers in the biotechnology space also have analyst coverage. Acurx Pharmaceuticals is a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections. Theravance Biopharma is engaged in the discovery, development, and commercialization of organ-selective medicines. Innoviva is a diversified holding company with a core royalties portfolio and a leading critical care and infectious disease platform. The peer group showed flat target revisions overall, though implied changes varied significantly.
| Company | Target revision | Implied change |
|---|---|---|
| Acurx Pharmaceuticals | 0.00% | +1,254.69% |
| Theravance Biopharma | 0.00% | — |
| Innoviva | 0.00% | +73.72% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.